BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Buti M, Mas A, Prieto M, Casafont F, González A, Miras M, Herrero JI, Jardi R, Esteban R. Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation. 2007;84:650-654. [PMID: 17876280 DOI: 10.1097/01.tp.0000277289.23677.0a] [Cited by in Crossref: 83] [Cited by in F6Publishing: 65] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Fox AN, Terrault NA. The option of HBIG-free prophylaxis against recurrent HBV. J Hepatol. 2012;56:1189-1197. [PMID: 22274310 DOI: 10.1016/j.jhep.2011.08.026] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
2 Karlas T, Hartmann J, Weimann A, Maier M, Bartels M, Jonas S, Mössner J, Berg T, Tillmann HL, Wiegand J. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only. Transpl Infect Dis. 2011;13:299-302. [PMID: 21159112 DOI: 10.1111/j.1399-3062.2010.00591.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
3 Mas A. Liver transplantation for hepatitis B virus. Pre-emptive and peri-operative prophylaxis. Dig Liver Dis 2009;41 Suppl 2:S191-4. [PMID: 19482256 DOI: 10.1016/S1590-8658(09)60443-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Fox AN, Terrault NA. Individualizing hepatitis B infection prophylaxis in liver transplant recipients. J Hepatol. 2011;55:507-509. [PMID: 21601598 DOI: 10.1016/j.jhep.2011.04.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
5 Rodríguez M, Buti M, Esteban R, Lens S, Prieto M, Suárez E, García-Samaniego J. Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). Gastroenterol Hepatol 2020;43:559-87. [PMID: 32778356 DOI: 10.1016/j.gastrohep.2020.03.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Zhang Y, Kang S, Fang W, Wu X, Liang W. Network meta-analysis on prophylactic regimens against recurrent hepatitis B virus infection after liver transplantation. Hepatobiliary Surg Nutr 2013;2:297-303. [PMID: 24570966 DOI: 10.3978/j.issn.2304-3881.2013.11.02] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
7 Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H. Application of nucleoside analogues to liver transplant recipients with hepatitis B. World J Gastroenterol 2015; 21(42): 12091-12100 [PMID: 26576094 DOI: 10.3748/wjg.v21.i42.12091] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
8 Tanaka T, Benmousa A, Marquez M, Therapondos G, Renner EL, Lilly LB. The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation. Clin Transplant. 2012;26:E561-E569. [PMID: 23061767 DOI: 10.1111/ctr.12022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
9 Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex (Engl Ed) 2021;86:403-32. [PMID: 34483073 DOI: 10.1016/j.rgmxen.2021.04.002] [Reference Citation Analysis]
10 Fernández I, Pascasio JM, Colmenero J; en nombre del grupo de trabajo para el VII consenso de la SETH., Autores participantes en el grupo de trabajo en representación de sus respectivos programas de trasplante hepático. Prophylaxis and treatment in liver transplantation. VII Consensus Document of the Spanish Society of Liver Transplantation. Gastroenterol Hepatol 2020;43:169-77. [PMID: 32094045 DOI: 10.1016/j.gastrohep.2019.11.005] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Roche B, Roque-Afonso AM, Nevens F, Samuel D. Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin. Transplantation. 2015;99:1321-1334. [PMID: 26038873 DOI: 10.1097/tp.0000000000000777] [Cited by in Crossref: 41] [Cited by in F6Publishing: 13] [Article Influence: 6.8] [Reference Citation Analysis]
12 Lindenger C, Castedal M, Cahlin C, Friman S. Excellent liver transplantation survival and prevention of hepatitis B recurrence using hepatitis B immunoglobulin and nucleoside or nucleotide analogue along with treating physician adherence to treatment protocol. Transplant Proc 2013;45:1188-92. [PMID: 23622656 DOI: 10.1016/j.transproceed.2012.10.007] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Kuo A, Gish R. Chronic Hepatitis B Infection. Clinics in Liver Disease 2012;16:347-69. [DOI: 10.1016/j.cld.2012.03.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
14 Villamil FG, Cairo FM. Hepatitis B virus: Prevention of recurrent infection. Clin Liver Dis (Hoboken) 2013;2:169-72. [PMID: 30992855 DOI: 10.1002/cld.224] [Reference Citation Analysis]
15 Wong TC, Fung JY, Lo CM. Prevention of recurrent hepatitis B infection after liver transplantation. Hepatobiliary & Pancreatic Diseases International 2013;12:465-72. [DOI: 10.1016/s1499-3872(13)60074-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
16 Kasraianfard A, Watt KD, Lindberg L, Alexopoulos S, Rezaei N. HBIG Remains Significant in the Era of New Potent Nucleoside Analogues for Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. International Reviews of Immunology 2015. [DOI: 10.3109/08830185.2014.921160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
17 Park JS, Gayam V, Pan CQ. Review article: preventing hepatitis B graft infection in hepatitis B patients after liver transplantation: immunoglobulin vs anti-virals. Aliment Pharmacol Ther. 2020;52:944-954. [PMID: 32743822 DOI: 10.1111/apt.15999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Xi ZF, Xia Q. Recent advances in prevention of hepatitis B recurrence after liver transplantation. World J Gastroenterol 2015; 21(3): 829-835 [PMID: 25624716 DOI: 10.3748/wjg.v21.i3.829] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
19 Saab S, Ham MY, Stone MA, Holt C, Tong M. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. Liver Transpl. 2009;15:413-420. [PMID: 19326401 DOI: 10.1002/lt.21712] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
20 Samuel D. [Liver transplantation for chronic hepatitis B]. Gastroenterol Clin Biol 2008;32:S25-33. [PMID: 18662607 DOI: 10.1016/S0399-8320(08)73262-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
21 Katz LH, Paul M, Guy DG, Tur-Kaspa R. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Transpl Infect Dis. 2010;12:292-308. [PMID: 20002355 DOI: 10.1111/j.1399-3062.2009.00470.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 60] [Article Influence: 6.1] [Reference Citation Analysis]
22 Yuefeng M, Weili F, Wenxiang T, Ligang X, Guiling L, Hongwei G, Wencai L, Xiaoguang W, Wei M, Zhongyi F. Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation. Clin Transplant. 2011;25:517-522. [PMID: 20560989 DOI: 10.1111/j.1399-0012.2010.01290.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
23 Jiménez-Pérez M, González-Grande R, Mostazo Torres J, González Arjona C, Rando-Muñoz FJ. Management of hepatitis B virus infection after liver transplantation. World J Gastroenterol 2015;21:12083-90. [PMID: 26576093 DOI: 10.3748/wjg.v21.i42.12083] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
24 Lai Q, Mennini G, Giovanardi F, Rossi M, Giannini EG. Immunoglobulin, nucleos(t)ide analogues and hepatitis B virus recurrence after liver transplant: A meta-analysis. Eur J Clin Invest 2021;51:e13575. [PMID: 33866547 DOI: 10.1111/eci.13575] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. Liver Transpl. 2011;17:1176-1190. [PMID: 21656655 DOI: 10.1002/lt.22354] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 8.3] [Reference Citation Analysis]
26 Roche B, Samuel D. Hepatitis: viral load predicts HBV recurrence after liver transplant. Nat Rev Gastroenterol Hepatol. 2010;7:657-658. [PMID: 21124520 DOI: 10.1038/nrgastro.2010.165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
27 Angus PW, Patterson SJ. Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? Liver Transpl. 2008;14 Suppl 2:S15-S22. [PMID: 18825721 DOI: 10.1002/lt.21614] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
28 Peters MG. Special populations with hepatitis B virus infection. Hepatology 2009;49:S146-55. [PMID: 19399810 DOI: 10.1002/hep.22965] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
29 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1296] [Cited by in F6Publishing: 1169] [Article Influence: 185.1] [Reference Citation Analysis]
30 Lens S, García-Eliz M, Fernández I, Castells L, Bonacci M, Mas A, Crespo G, Buti M, Prieto M, Forns X. Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation. Liver Int 2018;38:1940-50. [PMID: 29660249 DOI: 10.1111/liv.13858] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
31 Wang P, Tam N, Wang H, Zheng H, Chen P, Wu L, He X. Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis. PLoS One. 2014;9:e104480. [PMID: 25102072 DOI: 10.1371/journal.pone.0104480] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
32 Massoumi H, Martin P, Tan H. Management of chronic hepatitis B: . European Journal of Gastroenterology & Hepatology 2011;23:642-50. [DOI: 10.1097/meg.0b013e3283474add] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
33 Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc. 2019;118:7-38. [PMID: 30527436 DOI: 10.1016/j.jfma.2018.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
34 Gane E. Hepatitis B immunoglobulin immunoprophylaxis for hepatitis B: High, low, or no dose?1. Liver Transpl 2010;16:S36-9. [DOI: 10.1002/lt.22151] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
35 Rao W, Wu X, Xiu D. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int. 2009;22:387-394. [PMID: 19017304 DOI: 10.1111/j.1432-2277.2008.00784.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
36 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75. [PMID: 27044762 DOI: 10.3350/cmh.2016.22.1.18] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 19.2] [Reference Citation Analysis]
37 Beckebaum S, Sotiropoulos GC, Gerken G, Cicinnati VR. Hepatitis B and liver transplantation: 2008 update. Rev Med Virol 2009;19:7-29. [DOI: 10.1002/rmv.595] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
38 Cholongitas E, Papatheodoridis GV. Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. World J Gastroenterol 2013; 19(48): 9189-9197 [PMID: 24409047 DOI: 10.3748/wjg.v19.i48.9189] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
39 Gane E. Liver Transplantation for Chronic Hepatitis B and C. In: Thomas HC, Lok AS, Locarnini SA, Zuckerman AJ, editors. Viral Hepatitis. Oxford: John Wiley & Sons, Ltd; 2013. pp. 203-17. [DOI: 10.1002/9781118637272.ch15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 Buti M, Tabernero D, Mas A, Homs M, Prieto M, Rodríguez-Frías F, Casafont F, Casillas R, González A, Miras M, Herrero JI, Castells L, Esteban R. Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin. Transpl Infect Dis 2015;17:208-20. [PMID: 25641570 DOI: 10.1111/tid.12360] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
41 Roche B, Samuel D. Liver transplantation in viral hepatitis: Prevention of recurrence. Best Practice & Research Clinical Gastroenterology 2008;22:1153-69. [DOI: 10.1016/j.bpg.2008.12.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
42 Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant. 2013;13:353-362. [PMID: 23137006 DOI: 10.1111/j.1600-6143.2012.04315.x] [Cited by in Crossref: 104] [Cited by in F6Publishing: 83] [Article Influence: 10.4] [Reference Citation Analysis]
43 Beckebaum S, Kabar I, Cicinnati VR. Hepatitis B and C in liver transplantation: new strategies to combat the enemies. Rev Med Virol 2013;23:172-93. [PMID: 23239274 DOI: 10.1002/rmv.1734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
44 Campos-varela I, Castells L, Buti M, Vargas V, Bilbao I, Rodríguez-frías F, Jardí R, Charco R, Guardia J, Esteban R. Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues? Annals of Hepatology 2011;10:180-7. [DOI: 10.1016/s1665-2681(19)31567-4] [Cited by in Crossref: 15] [Article Influence: 1.4] [Reference Citation Analysis]
45 Ku W, Wang U, Nguyen MH. Efficacy and effectiveness of anti-HBV therapy with early withdrawal of HBIG prophylaxis to prevent HBV recurrence following liver transplantation. Expert Opin Biol Ther. 2015;15:665-677. [PMID: 25865452 DOI: 10.1517/14712598.2015.1025045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
46 Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex 2021:S0375-0906(21)00061-6. [PMID: 34384668 DOI: 10.1016/j.rgmx.2021.04.002] [Reference Citation Analysis]
47 Gane EJ. Is hepatitis B immune globulin still needed after liver transplantation for chronic hepatitis B? Hepatology 2017;66:1023-5. [PMID: 28555932 DOI: 10.1002/hep.29292] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
48 Lou B, Ma G, Lv F, Yuan Q, Xu F, Dong Y, Lin S, Tan Y, Zhang J, Chen Y. Baseline Quantitative Hepatitis B Core Antibody Titer Is a Predictor for Hepatitis B Virus Infection Recurrence After Orthotopic Liver Transplantation. Front Immunol 2021;12:710528. [PMID: 34777339 DOI: 10.3389/fimmu.2021.710528] [Reference Citation Analysis]
49 Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK. Current management of hepatitis B virus infection before and after liver transplantation. Liver International 2009;29:1294-305. [DOI: 10.1111/j.1478-3231.2009.02085.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 4.0] [Reference Citation Analysis]
50 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 121] [Article Influence: 10.9] [Reference Citation Analysis]
51 Roque-Afonso AM. Hepatitis B virus cellular immunity after liver transplantation: a role in preventing hepatitis B virus recurrence? Liver Transpl 2009;15:269-72. [PMID: 19242997 DOI: 10.1002/lt.21729] [Reference Citation Analysis]
52 Buti M, García-samaniego J, Prieto M, Rodríguez M, Sánchez-tapias JM, Suárez E, Esteban R. Documento de consenso de la AEEH sobre el tratamiento de la infección por el virus de la hepatitis B (2012). Gastroenterología y Hepatología 2012;35:512-28. [DOI: 10.1016/j.gastrohep.2012.04.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
53 Maiwall R, Kumar M. Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation. J Clin Transl Hepatol 2016;4:54-65. [PMID: 27047773 DOI: 10.14218/JCTH.2015.00041] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
54 Marzano A. The prevention of viral recurrence in the long term. Digestive and Liver Disease 2009;41:S195-7. [DOI: 10.1016/s1590-8658(09)60444-8] [Cited by in Crossref: 10] [Article Influence: 0.8] [Reference Citation Analysis]
55 Stravitz RT, Shiffman ML, Kimmel M, Puri P, Luketic VA, Sterling RK, Sanyal AJ, Cotterell AH, Posner MP, Fisher RA. Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation. Liver Int. 2012;32:1138-1145. [PMID: 22348467 DOI: 10.1111/j.1478-3231.2012.02770.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
56 Roche B, Samuel D. Treatment of patients with HBV-related decompensated cirrhosis and liver transplanted patients. Clin Liver Dis. 2013;17:451-473. [PMID: 23905816 DOI: 10.1016/j.cld.2013.05.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
57 Duvoux C, Belli LS, Fung J, Angelico M, Buti M, Coilly A, Cortesi P, Durand F, Féray C, Fondevila C, Lebray P, Martini S, Nevens F, Polak WG, Rizzetto M, Volpes R, Zoulim F, Samuel D, Berenguer M. 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation. Aliment Pharmacol Ther 2021;54:583-605. [PMID: 34287994 DOI: 10.1111/apt.16374] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
58 John S, Andersson KL, Kotton CN, Hertl M, Markmann JF, Cosimi AB, Chung RT. Prophylaxis of hepatitis B infection in solid organ transplant recipients. Therap Adv Gastroenterol 2013;6:309-19. [PMID: 23814610 DOI: 10.1177/1756283X13487942] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
59 Samuel D. The option of liver transplantation for hepatitis B: Where are we? Digestive and Liver Disease 2009;41:S185-9. [DOI: 10.1016/s1590-8658(09)60442-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
60 Lenci I, Tisone G, Di Paolo D, Marcuccilli F, Tariciotti L, Ciotti M, Svicher V, Perno CF, Angelico M. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol. 2011;55:587-593. [PMID: 21251938 DOI: 10.1016/j.jhep.2010.12.036] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 5.5] [Reference Citation Analysis]
61 Saab S, Desai S, Tsaoi D, Durazo F, Han S, McClune A, Holt C, Farmer D, Goldstein L, Busuttil RW. Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy. Am J Transplant. 2011;11:511-517. [PMID: 21299826 DOI: 10.1111/j.1600-6143.2010.03416.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
62 Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008;48:1460-6. [PMID: 18925641 DOI: 10.1002/hep.22524] [Cited by in Crossref: 132] [Cited by in F6Publishing: 109] [Article Influence: 9.4] [Reference Citation Analysis]
63 Raab CP. Passive immunization. Prim Care 2011;38:681-91, viii. [PMID: 22094139 DOI: 10.1016/j.pop.2011.07.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
64 Katz LH, Tur-Kaspa R, Guy DG, Paul M. Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation. Cochrane Database Syst Rev. 2010;CD006005. [PMID: 20614442 DOI: 10.1002/14651858.cd006005.pub2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
65 Pol S, Sogni P. [Treatment of chronic hepatitis B: adherence and safety]. Gastroenterol Clin Biol. 2010;34 Suppl 2:S142-S148. [PMID: 21095518 DOI: 10.1016/s0399-8320(10)70034-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Jiang L, Jiang LS, Cheng NS, Yan LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2009; 15(20): 2489-2499 [PMID: 19468999 DOI: 10.3748/wjg.15.2489] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
67 Ishigami M, Onishi Y, Ito T, Katano Y, Ito A, Hirooka Y, Kiuchi T, Goto H. Anti-hepatitis B surface immunoglobulin reduction in early postoperative period after liver transplantation in hepatitis B virus-positive patients: HBIg reduction in early post-transplant period. Hepatology Research 2011;41:1189-98. [DOI: 10.1111/j.1872-034x.2011.00884.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
68 Buchanan C, Tran TT. Current status of liver transplantation for hepatitis B virus. Clin Liver Dis. 2011;15:753-764. [PMID: 22032527 DOI: 10.1016/j.cld.2011.08.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
69 Patterson SJ, Angus PW. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues. Curr Opin Organ Transplant 2009;14:225-30. [PMID: 19373086 DOI: 10.1097/MOT.0b013e32832b1f32] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]